Efficacy, Safety and Immunogenicity of BI 695501 Versus Humira® in Patients With Moderate to Severe Chronic Plaque Psoriasis

Completed · Phase 3

Conditions studied: Psoriasis

In brief

To evaluate the efficacy and to compare efficacy and safety of BI 695501 versus Humira in patients with moderate to severe chronic plaque psoriasis.

Key facts

Study ID

NCT02850965

Run by

Boehringer Ingelheim

People needed

318

Starts

2016-08-17

Expected to finish

2018-01-17

Last updated by the study team

2019-02-08

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females aged >=18 to =<80 years who have a diagnosis of moderate to severe chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study drug (a self-reported diagnosis confirmed by the investigator is acceptable), and which has been stable for the last 2 months with no changes in morphology or significant flares at both Screening and Baseline (Randomization):
• involved body surface area (BSA) >= 10% and
• Psoriasis Area and Severity Index (PASI) score >= 12 and
• static Physician's Global Assessment (sPGA) score of >= 3.
• Participants of reproductive potential (childbearing potential ) must be willing and able to use highly effective methods of birth control per International Council for Harmonization (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly during the trial and for 6 months following completion or discontinuation from the trial medication.
• Signed and dated written informed consent in accordance with Good Clinical Practice (GCP) and local legislation prior to admission to the trial.
• Patients who are candidates for systemic therapy.

You may not qualify if…

• Active ongoing inflammatory diseases other than psoriasis that might confound trial evaluations according to investigator's judgment.
• Previous treatment with more than 1 biological agent, or adalimumab or adalimumab biosimilar. No prior biologic exposure within last 6 months of screening.
• Patients with a significant disease other than psoriasis and/or a significant uncontrolled disease (such as, but not limited to, nervous system, renal, hepatic, endocrine, hematological, autoimmune or gastrointestinal disorders).
• Major surgery performed within 12 weeks prior to randomization or planned within 6 months after screening, e.g., total hip replacement.
• Any documented active or suspected malignancy or history of malignancy within 5 years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix.
• Patients who must or wish to continue the intake of restricted medications or any drug considered likely to interfere with the safe conduct of the trial.
• Currently enrolled in another investigational device or drug study, or less than 30 days since ending another investigational device or drug study(s), or receiving other investigational treatment(s).
• Chronic alcohol or drug abuse
• Women who are pregnant, nursing, or who plan to become pregnant during the course of this study or within the period at least 6 months following completion or discontinuation from the trial.
• Forms of psoriasis (e.g., pustular, erythrodermic and guttate) other than chronic plaque psoriasis. Drug-induced psoriasis (i.e., new onset or current exacerbation from e.g., beta blockers or lithium).
• Primary or secondary immunodeficiency (history of, or currently active), including known history of HIV infection or a positive HIV test at screening (per the investigator discretion and where mandated by local authorities).
• Known chronic or relevant acute tuberculosis; no evidence of active tuberculosis.
• Known clinically significant coronary artery disease, significant cardiac arrhythmias, moderate to severe congestive heart failure (New York Heart Association Classes III or IV) or interstitial lung disease observed on chest X-ray.
• History of a severe allergic reaction, anaphylactic reaction, or hypersensitivity to a previously used biological drug or its excipients.
• Positive serology for hepatitis B virus (HBV) or hepatitis C virus (HCV).
• Receipt of a live/attenuated vaccine within 12 weeks prior to the Screening Visit; patients who are expecting to receive any live/attenuated virus or bacterial vaccinations during the trial or up to 3 months after the last dose of trial drug.
• Any treatment (including biologic therapies) that, in the opinion of the investigator, may place the patient at unacceptable risk during the trial.
• Known active infection of any kind (excluding fungal infections of nail beds), any major episode of infection requiring hospitalization or treatment with intravenous (i.v.) anti infectives within 4 weeks of the Screening Visit
• Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 times upper limit of normal (ULN) at Screening.
• Hemoglobin < 8.0 g/dL at Screening.
• Platelets < 100,000/µL at Screening.
• Leukocyte count < 4000/µL at Screening.
• Creatinine clearance < 60 mL/min/1.73 m2 at Screening.
• Patients with a history of any clinically significant adverse reaction to murine or chimeric proteins, or natural rubber and latex, including serious allergic reactions.

Where it is running

• Alliance Dermatology and MOHS Center PC — Phoenix, Arizona, United States
• Southern California Dermatology Inc. — Santa Ana, California, United States
• Avail Clinical Research, LLC — DeLand, Florida, United States
• Jacksonville Center for Clinical Research — Jacksonville, Florida, United States
• New Horizon Research Center — Miami, Florida, United States
• Renstar Medical Research — Ocala, Florida, United States
• Clinical Research Atlanta — Stockbridge, Georgia, United States
• Advanced Clinical Research — Boise, Idaho, United States
• Heartland Research Associates, LLC — Wichita, Kansas, United States
• Lynn Health Science Institute — Oklahoma City, Oklahoma, United States
• Altoona Center for Clinical Research, P.C. — Duncansville, Pennsylvania, United States
• Medical Research South — Charleston, South Carolina, United States
• Menter Dermatology Research Institute — Dallas, Texas, United States
• Dorothea — Chomutov, Czechia
• MU Dr. Helena Korandova s.r.o., Olomouc-Povel — Olomouc-Povel, Czechia
• University Hospital Ostrava — Ostrava, Czechia
• HOMEA spol. s.r.o., Pardubice — Pardubice, Czechia
• Univ. Hospital Kralovske Vinohrady — Prague, Czechia
• MU Dr. Jaroslav Dragon, Ústí nad Labem — Ústí nad Labem, Czechia
• Center for Clinical and Basic Research, Tallinn — Tallinn, Estonia
• Hospital of South-Estonia Ltd, Võru Maakond — Võru Maakond, Estonia
• Rothhaar Studien GmbH — Berlin, Germany
• Rosenparkklinik GmbH, Darmstadt — Darmstadt, Germany
• Universitätsklinikum Carl Gustav Carus Dresden — Dresden, Germany
• Pinnacle Research Group, LLC — Anniston, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.